Cargando…

Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study

BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic....

Descripción completa

Detalles Bibliográficos
Autores principales: Balck, Alexander, Föh, Bandik, Borsche, Max, Rahmöller, Johann, Vollstedt, Eva-Juliane, Waldeck, Frederike, Käding, Nadja, Twesten, Christoph, Mischnik, Alexander, Gillessen-Kaesbach, Gabriele, Ehlers, Marc, Sina, Christian, Taube, Stefan, Busch, Hauke, Rupp, Jan, Katalinic, Alexander, Klein, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261226/
https://www.ncbi.nlm.nih.gov/pubmed/35799167
http://dx.doi.org/10.1186/s12889-022-13666-z
_version_ 1784742226349260800
author Balck, Alexander
Föh, Bandik
Borsche, Max
Rahmöller, Johann
Vollstedt, Eva-Juliane
Waldeck, Frederike
Käding, Nadja
Twesten, Christoph
Mischnik, Alexander
Gillessen-Kaesbach, Gabriele
Ehlers, Marc
Sina, Christian
Taube, Stefan
Busch, Hauke
Rupp, Jan
Katalinic, Alexander
Klein, Christine
author_facet Balck, Alexander
Föh, Bandik
Borsche, Max
Rahmöller, Johann
Vollstedt, Eva-Juliane
Waldeck, Frederike
Käding, Nadja
Twesten, Christoph
Mischnik, Alexander
Gillessen-Kaesbach, Gabriele
Ehlers, Marc
Sina, Christian
Taube, Stefan
Busch, Hauke
Rupp, Jan
Katalinic, Alexander
Klein, Christine
author_sort Balck, Alexander
collection PubMed
description BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life. METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms. DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases. TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418, Registered on 28 October 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13666-z.
format Online
Article
Text
id pubmed-9261226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92612262022-07-07 Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study Balck, Alexander Föh, Bandik Borsche, Max Rahmöller, Johann Vollstedt, Eva-Juliane Waldeck, Frederike Käding, Nadja Twesten, Christoph Mischnik, Alexander Gillessen-Kaesbach, Gabriele Ehlers, Marc Sina, Christian Taube, Stefan Busch, Hauke Rupp, Jan Katalinic, Alexander Klein, Christine BMC Public Health Study Protocol BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life. METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms. DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases. TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418, Registered on 28 October 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13666-z. BioMed Central 2022-07-07 /pmc/articles/PMC9261226/ /pubmed/35799167 http://dx.doi.org/10.1186/s12889-022-13666-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Balck, Alexander
Föh, Bandik
Borsche, Max
Rahmöller, Johann
Vollstedt, Eva-Juliane
Waldeck, Frederike
Käding, Nadja
Twesten, Christoph
Mischnik, Alexander
Gillessen-Kaesbach, Gabriele
Ehlers, Marc
Sina, Christian
Taube, Stefan
Busch, Hauke
Rupp, Jan
Katalinic, Alexander
Klein, Christine
Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title_full Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title_fullStr Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title_full_unstemmed Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title_short Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
title_sort protocol of the luebeck longitudinal investigation of sars-cov-2 infection (elisa) study – a prospective population-based cohort study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261226/
https://www.ncbi.nlm.nih.gov/pubmed/35799167
http://dx.doi.org/10.1186/s12889-022-13666-z
work_keys_str_mv AT balckalexander protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT fohbandik protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT borschemax protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT rahmollerjohann protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT vollstedtevajuliane protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT waldeckfrederike protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT kadingnadja protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT twestenchristoph protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT mischnikalexander protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT gillessenkaesbachgabriele protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT ehlersmarc protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT sinachristian protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT taubestefan protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT buschhauke protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT ruppjan protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT katalinicalexander protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy
AT kleinchristine protocoloftheluebecklongitudinalinvestigationofsarscov2infectionelisastudyaprospectivepopulationbasedcohortstudy